A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)
An Open-Label Phase 2 Study to Evaluate PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma
Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
A PHASE2 clinical study on VHL - Von Hippel-Lindau Syndrome and VHL Gene Inactivation, this trial is ongoing. The trial is conducted by Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) and has accumulated 27 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
27 versions recorded-
Jan 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
▶ Show 22 earlier versions
-
Jan 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2022 — Dec 2022 [monthly]
Active Not Recruiting PHASE2
-
Apr 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2
-
Jul 2019 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Jul 2019 [monthly]
Active Not Recruiting PHASE2
-
Feb 2019 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting PHASE2
-
Feb 2018 — Mar 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
For direct contact, visit the study record on ClinicalTrials.gov .